Research on hormone therapy and its effects. Covers menopause symptom relief, bronchiectasis risk, dementia links, and Alzheimer's risk.
A new meta-analysis of randomized studies involving 4,141 prostate cancer patients found no difference in cardiovascular deaths between those receiving androgen deprivation therapy (ADT) and those who didn't. The study suggests that ADT may not increase the risk of fatal heart attacks for men without a history of heart disease.
Researchers at Addex Pharmaceuticals have discovered a novel interaction between GLP-1 and GIP receptors, which has the potential to trigger new therapies for Type 2 diabetes. The discovery was made possible by the company's allosteric modulation platform and could lead to the development of orally available small molecule treatments.
A new mathematical model predicts individual patient responses to therapy and identifies optimal treatments for advanced prostate cancer. The model incorporates personalized data, including tumor cell characteristics, to provide more accurate treatment decisions.
Researchers identify a new way to boost the aged immune response to flu viruses by inhibiting PGD2. They also discover that targeting BRAF in thyroid cancers could restore the efficacy of RAI therapy. Additionally, exploring EGFR as a therapeutic target for Cushing disease may provide new treatment options.
A recent study found that women taking combination estrogen and progestin menopausal hormone therapy are at a greater risk of developing breast cancer if they experience new onset breast tenderness. In contrast, women on estrogen alone without breast tenderness did not have an increased risk of breast cancer.
Researchers found that introducing a novel histone deacetylase inhibitor can reverse tumor's survival strategy and stop resistance, leading to higher cell death rates. This approach may prevent hormone therapy resistance in patients with estrogen receptor-positive breast cancer.
Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease. The treatment improved overall survival by 23% and disease-specific survival by 43% compared to hormone therapy alone.
Research shows that repeated administrations of radionuclide therapy with 188Re-HEDP improve overall survival rates, reducing pain in prostate cancer patients with hormone-refractory bone metastases. The study found significant increases in post-treatment survival for patients receiving two or three therapies.
Scientists at UH outline a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's, and cardiovascular diseases. They identify estrogen receptor beta (ERβ) as a potential target for these treatments.
Post-menopausal women experiencing new onset breast tenderness after starting combination hormone therapy may have an increased risk of breast cancer compared to those without breast tenderness. Higher breast density is associated with a higher risk of breast cancer, with extremely dense breasts posing a four to six times higher risk.
Researchers have identified estrogen receptors in specific brain areas that influence metabolism, weight gain, and fertility. Deleting these receptors from mice resulted in significant weight gain and metabolic changes.
Researchers at the University of Houston have discovered that estradiol, a naturally occurring estrogen hormone, plays a prominent role in regulating body functions in both females and males. The study found that an imbalance of estradiol levels can result in metabolic diseases, including diabetes, obesity, and cardiovascular disease.
Researchers found a positive association between HRT use and asthma hospitalizations, with women taking the drug for over 10 years facing a higher risk. The study suggests that women on HRT may need to consider stopping hormone therapy if they experience severe asthma symptoms.
A 12-year update of the Breast International Group 1-98 trial shows that letrozole reduces the risk of breast cancer relapse by 18% and death by 21% compared to tamoxifen after surgery. The study provides long-term reassurance on the efficacy of aromatase inhibitors in preventing breast cancer recurrence.
A phase III clinical trial shows that abiraterone acetate significantly improves fatigue in men with metastatic castration-resistant prostate cancer. The treatment also delays the progression of fatigue and has a potential survival benefit.
A phase III clinical trial has shown that combining everolimus and exemestane significantly improves progression-free survival for women with advanced breast cancer resistant to hormonal therapy. The combination treatment resulted in an improved survival of nearly seven months compared to women treated with only exemestane.
Breast cancer researchers identify FGFR3 as a key protein responsible for tumor growth and resistance to hormone therapies. This discovery may lead to the development of novel drugs targeting this protein to treat recurrent breast cancers.
Researchers at UCLA found that estrogen treatment can reverse the progression of pulmonary hypertension to heart failure and restore lung and ventricle structure and function. The study suggests that even short-term estrogen therapy may suffice to reverse the disease, offering new potential therapeutic applications for human patients.
A new study from the University of Michigan found that over 25% of women in the metro Detroit area have experienced ongoing vulvar pain, while only 2% sought treatment. The study sheds light on the demographics and characteristics of vulvodynia, a condition causing unexplained pain at the vagina's opening.
Researchers found a 2.5 times higher prevalence of HFI in modern female participants compared to historic skulls, with average age of onset dropping drastically. Hormonal imbalance, lifestyle factors, and fertility habits may contribute to the condition.
Researchers found that low-risk patients aged 60 or older with small tumors and low-grade disease have mortality rates comparable to the general population. These patients may not benefit from adjuvant therapy, contradicting previous recommendations for almost all patients with hormone-responsive disease.
Researchers at Lund University have developed a new treatment option for advanced prostate cancer by targeting cancer stem cells with a STAT3-inhibitor. The study found that galiellalactone, a natural compound, has inhibitory effects on the growth of prostate cancer cells and prevents tumour growth and spreading.
A recent study found that menopause has little to no impact on the risk of developing diabetes. Instead, lifestyle changes such as losing 7% of body weight and exercising for at least 150 minutes a week can significantly lower the risk of diabetes in postmenopausal women.
Men are less susceptible to inflammatory diseases due to higher testosterone levels, which suppress phospholipase D and reduce pro-inflammatory substance production. This knowledge can inform new therapies for inflammatory diseases, requiring 'customized' treatments for men and women.
Researchers found that women are more likely to survive after gastrointestinal surgeries than men, particularly those before menopause. Female patients had lower mortality rates in various procedures, suggesting that female hormones may enhance the immune system.
Cervical ripening in preterm and term births has distinct processes, with preterm ripening caused by inflammation-induced changes and not an acceleration of the physiologic process. The study aims to determine effective therapies for each cause of preterm birth.
Researchers developed a new alpha-emitter-based therapy that effectively targets and cures neuroendocrine tumors without harming healthy tissues. The treatment, called 213Bi-DOTATOC peptide receptor alpha-therapy, showed promising results in patients with liver metastases resistant to beta-particle peptide therapy.
A new study suggests that daily testosterone therapy can improve verbal learning and memory in postmenopausal women, reducing their risk of cognitive decline. The research found significant benefits after six months of treatment.
A new targeted therapy, G-1, has been shown to halt the growth of tumors in animals with advanced prostate cancer resistant to hormone therapy. The treatment works by targeting and activating protein GPR30, which sensitizes tumor cells to its inhibiting effects.
A new therapeutic vaccine targets ghrelin to suppress appetite and increase energy expenditure in mice, reducing food intake by up to 82% after a single vaccination. The study suggests an alternate treatment approach for obesity that can be used in combination with diet and exercise.
Researchers at UNC School of Medicine have shown that transplantation of adult stem cells enriched with IGF-I can help mend bone fractures not healing properly. The treatment speeds up the healing process, restoring bone formation and strength.
Girls with anorexia nervosa saw significant increases in bone density at the spine and hip after receiving physiological estrogen therapy, according to a new study. However, they still had lower bone density than healthy-weight controls.
Men with prostate cancer treated with hormone deprivation therapy may be at increased risk of developing diabetes or metabolic syndrome. According to the study, men in the ADT group had a twofold increased probability of having diabetes compared to those who did not receive hormonal therapy.
Women with early-stage hormone receptor-sensitive breast cancer who received zoledronic acid alongside standard hormone therapy had a significantly lower risk of cancer returning (32%) compared to those on hormone therapy alone. The treatment's anticancer benefit persisted even after stopping treatment for over two years.
Researchers at Thomas Jefferson University discovered a biomarker Stat5 in breast cancer that predicts patient response to anti-estrogen therapy tamoxifen. Women with active Stat5 have an increased likelihood of responding to the treatment, while those without it are at a higher risk of dying from breast cancer.
A new predictive test developed from gene expression microarrays identified patients with a high probability of survival following chemotherapy for breast cancer. The test had a positive predictive value of 56 percent and showed significant association between predicted sensitivity to treatment and improved distant relapse-free survival.
Research published in the Journal of NeuroInterventional Surgery suggests that taking oral contraceptives or hormone replacement therapy may reduce the risk of developing cerebral aneurysms. The study found that women with cerebral aneurysms were less likely to have taken these medications and had an earlier average age of menopause.
A new study published in The Journal of Urology found that testosterone therapy does not cause rapid growth of prostate cancer in men with untreated or low-risk prostate cancer. Testosterone treatment was associated with improved symptoms and quality of life, without increasing the risk of cancer progression.
A recent study suggests that estrogen-only hormone therapy may decrease the risk of breast cancer in women who have had a hysterectomy. However, experts caution against long-term use due to unknown consequences and conflicting evidence from previous studies.
Researchers at Beth Israel Deaconess Medical Center have found that a synthetic form of leptin can restore fertility and reduce the risk of bone fractures in lean women with hypothalamic amenorrhea. The study shows significant improvements in hormone levels, menstrual cycles, and bone density after treatment with metreleptin.
Dr. Jan-Åke Gustafsson leads a team to develop new methods for treating severe prostate cancer using plant-derived and synthetic chemicals. The team aims to create drugs that target new areas of the androgen signaling system, offering innovative approaches to slowing cancer growth.
A new study published in the New England Journal of Medicine found that treating girls with Turner syndrome with low doses of estrogen and growth hormone significantly increased their adult height. The treatment also showed modest synergy between growth hormone and low-dose estrogen in promoting growth.
A new study found that combining 6 months of hormone therapy with radiotherapy significantly improved survival rates for men with locally advanced prostate cancer. The treatment reduced the risk of death from prostate cancer by half and deaths from any cause by a third compared to radiation alone.
A study found that authors receiving industry funding were more likely to publish articles promoting menopausal hormone therapy, which may encourage physicians to continue prescribing the therapies. The study's authors caution healthcare providers to exercise caution when reading such articles.
Researchers analyzed 47 studies involving over 327,000 patients with chronic kidney disease and found no significant association between serum phosphorus, parathyroid hormone, or calcium levels and the risk of death or cardiovascular events. The study suggests that current clinical guidelines for mineral metabolism in patients with kid...
A small clinical trial suggests traditional Chinese acupuncture can curb the severity of menopausal hot flushes and other symptoms. The treatment showed cumulative benefits, with significant improvements in somatic and psychological symptoms but minimal impact on urogenital symptoms.
Researchers found that Hashimoto's thyroiditis symptoms persist even when thyroid function is normal, affecting quality of life. Women with higher levels of anti-thyroid antibodies experienced more symptoms.
New research reveals environmental progestogens can cause sterility in frogs, particularly when exposed during early life stages. The study, conducted at Uppsala University, found that even low concentrations of levonorgestrel can lead to abnormal ovarian and oviduct development in female tadpoles.
Researchers found that people taking bisphosphonates lived longer than those without osteoporosis and even gained an extra five years of life. The study, published in the Journal of Clinical Endocrinology and Metabolism, suggests a possible link between bone health and toxic metal release.
The European Menopause and Andropause Society publishes two important position statements covering common management problems in post-reproductive health, including hormone therapy options for Cardiovascular disease and Osteoporosis. The statements provide summary recommendations for clinicians to manage menopause-related symptoms.
Researchers found a protein called FUS that inhibits prostate cancer cell growth and activates pathways leading to cell suicide. Higher levels of FUS correlate with less aggressive cancer and longer survival.
A large cohort study found that hormone therapy started at menopause increases breast cancer risk, particularly among women who start therapy before or soon after menopause. The study's results support previous findings and provide new insights into the relationship between timing of hormone therapy and breast cancer risk.
A study published in JAMA Network found that escitalopram significantly reduced the frequency and severity of menopausal hot flashes in healthy women. The medication was associated with a 47% decrease in hot flash frequency compared to placebo, making it a nonhormonal option for treating menopausal hot flashes.
The TEAM study found that sequential treatment of tamoxifen followed by exemestane yields a comparable disease-free survival rate to exemestane alone, yet with distinct side effect profiles. This implies the need to tailor treatment regimens for specific patient groups.
Researchers at UNC Chapel Hill are conducting a clinical trial to determine if estrogen replacement therapy can help prevent depression and cardiovascular illness in women between 45-55. The study, funded by the NIH, aims to identify which women will benefit from estradiol treatment during perimenopause.
US women who stopped hormone therapy showed significant declines in ductal carcinoma in situ (DCIS) and invasive breast cancer. The study of over 2 million mammogram screenings found a direct link between reduced hormone therapy and decreased breast cancer incidence.
Scientists from Scripps Research Institute have identified a novel synthetic activator of RORα and RORγ nuclear receptors, which play key roles in human metabolism and immune function. This discovery could lead to new therapeutic approaches for diseases such as diabetes and osteoporosis.
Researchers found a 26% decreased risk of dementia for women taking hormone therapy only at midlife, while late-life use increased risk by 48%. Midlife and late-life use had similar dementia risks for women not on hormone therapy.
A new study found a 30-40% higher risk of colorectal cancer among men treated with hormone-based therapy for prostate cancer. The study suggests continued routine preventive care, including colorectal cancer screening, is essential during prostate cancer treatment.
Research from Tel Aviv University finds that stress and anxiety are major contributors to IVF-related depression. Hormone therapy plays a lesser role in inducing depression during IVF treatment.